Topic: Shingles

GSK's shingles shot Shingrix has routinely beaten expectations since its U.S. rollout, and its second-quarter performance was no different.

Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors.

GSK's Shingrix carried high expectations, but it turns out that even those ambitious projections weren't high enough.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.

After picking up key regulatory nods in the U.S., GlaxoSmithKline’s Shingrix is well on its way to expanding its reach into Europe.

The CDC committee in charge of vaccination policy in the U.S. endorsed GlaxoSmithKline's Shingrix over the older shot, Merck's Zostavax.

Marking a big step in its march toward potential approval, GlaxoSmithKline’s shingles vaccine candidate Shingrix won the support of an FDA panel.

U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.

Shingrix met its goal in a study examining whether it can protect older adults who previously received Merck’s Zostavax.